首页> 中文期刊>现代检验医学杂志 >抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义

抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义

     

摘要

Objective To detect the anti EZH2 autoantibodies IgG expression in hepatocellular carcinoma patient's serum samples and investigate the relationship of anti EZH2 autoantibodies IgG expression with clinicopathological parameters.Methods ELISA method was used to detect the anti EZH2 autoantibodies in serum of 120 cases of HCC patients and compared with 115 healthy controls.Results Serum anti EZH2 antibodies in patients with hepatocellular carcinoma group the content of IgG was 2.015±0.568 μg/ml group,anti EZH2 antibodies IgG content control health was 1.185±0.289 μg/ml.There was significant difference between two groups (t=12.48,P<0.001).Anti EZH2 antibodies of IgG in serum of pa ticnts with hepatocellular carcinoma was up-regulated and the degree of tumor size,tumor the degree of differentiation,TNM grading and intrahepatic metastasis (t=8.485 ~ 57.93,P<0.001).And age,sex,drinking,whether HBV infection had no significant difference (t=1.22~5.20,P>0.05).Conclusion The expression of anti EZH2 autoantibodies in serum was related to the occurrence and development of hepatocellular carcinoma,and the detection of serum anti EZH2 autoantibodies in serum of liver cancer may be helpful to judge the malignant behavior and prognosis of hepatocellular carcinoma (HCC).which may be used as a refcrcnce for the evaluation of the prognosis of HCC patients with IgG antibody against IgG.%目的 探讨肝癌患者血清中抗EZH2自身抗体IgG的表达与临床病理参数的关系和意义.方法 采用ELISA法检测120例肝癌患者血清中的抗EZH2自身抗体IgG抗体并与115例健康对照组比较.结果 肝癌组患者血清抗EZH2自身抗体IgG含量为2.015±0.568 μg/ml,健康对照组抗EZH2自身抗体IgG含量为1.185±0.289 μg/ml,两组比较差异有统计学意义(t=12.48,P<0.001);肝癌患者血清抗EZH2自身抗体IgG的上调表达程度与肿瘤大小、肿瘤分化程度、TNM分级和肝内转移相关(t=8.485~57.93,P<0.001);与年龄、性别、饮酒和HBV是否感染等无明显差异(t=1.22~5.20,P>0.05).结论 血清抗EZH2自身抗体IgG表达上调与肝癌的发生发展相关,检测肝癌血清抗EZH2自身抗体IgG可能有利于判断肝癌的恶性行为以及预后评估有参考价值.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号